IntReALL 2010

Portrait of Dr von Stackelberg, Scientific Coordinator of IntReALL 2010

Dr Arend von Stackelberg

Scientific Coordinator of IntReALL 2010, based at Charité - Universitätsmedizin Berlin, Germany

Research field

Leukaemia

If you like this
If you want to know more
Research Profile

Who?

"I am convinced of the fact that the survival rates of children with relapsed acute lymphoblastic leukaemia (ALL) can still be improved. We were able to save more children’s lives and IntReALL will take us even a step further”, says Dr Arend von Stackelberg.

Why?

The main goal of this large international study is to improve the remission and survival rate of children with relapsed ALL by optimising their treatment. This goal can be reached by integrating a large number of patients into the study.

What?

Relapsed ALL is a rare disease and children still die from it. To develop an optimal treatment within a reasonable timeframe, it's important to study the therapies of a sufficient number of patients.To this end, international collaboration is crucial. A new drug for these children will also be investigated within this study.

How?

With the collaboration of 20 countries, about 250 hospitals and small and medium sized enterprises in the field of biotechnology and IT, this study will benefit from the know-how of all the international investigators. Furthermore we are linked to the networks on paediatric oncology, drug development and parent organisations.

Improving the treatment of leukaemia in children with relapsed ALL

In the Picture
In the Picture
IntReALL project website European Network for Cancer Research in Children and Adolescents International Confederation of Childhood Cancer Parent Organizations Com­pe­tence Net­work Pa­ed­ia­tric On­co­lo­gy and Hae­ma­to­lo­gy In Focus article 'Rare disease, common struggle' PDF versionPDF version
Image credits

Background image: IntReALL 2010

Portrait of the project coordinator: IntReALL 2010

Timeline (in chronological order): IntReALL 2010